FDAnews Drug Daily Bulletin

Roche’s GA101 Met Goals in Stage One of Trial to Replace Rituxan

Feb. 1, 2013
A A
Roche Holding AG said a next-generation blood cancer drug met its target in the first stage of a trial that could help the treatment replace top-seller Rituxan in patients with chronic lymphocytic leukemia.
Bloomberg